Regular Consumption of Low Levels of Caffeine During Pregnancy Linked to Slightly Shorter Children

Regular Consumption of Low Levels of Caffeine During Pregnancy Linked to Slightly Shorter Children

Main
Exposure to caffeine in the womb, even low amounts, may lead to shorter height in childhood, suggests a new study from the National Institutes of Health (NIH). Children of women with low caffeine intake (including below the current recommendation of 200 milligrams [mg] per day) during pregnancy were slightly shorter than children born to women who consumed no caffeine while pregnant, and the gaps in height widened to 2 centimeters (cm) between ages 4 and 8 years old. The findings were published October 31 in JAMA Network Open.“Our findings suggest that even low caffeine intake during pregnancy can have long-term effects on child growth,” said the co-lead author, Katherine Grantz, MD, in a press release.It’s important to note that the observed height differences were small — less than an inch —…
Read More
FDA Approves Hemgenix, First Gene Therapy to Treat Adults With Hemophilia B

FDA Approves Hemgenix, First Gene Therapy to Treat Adults With Hemophilia B

Main
The U.S. Food and Drug Administration (FDA) approved Hemgenix (etranacogene dezaparvovec) gene therapy for the treatment of adults with hemophilia B (congenital factor 9 deficiency) who currently use factor 9 prophylaxis therapy; have current or historical life-threatening hemorrhage; or have repeated, serious spontaneous bleeding episodes.Despite advancements in the treatment of hemophilia, the prevention and treatment of bleeding episodes can adversely impact individuals’ quality of life, said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, in a press release. “Today’s approval provides a new treatment option for patients with hemophilia B and represents important progress in the development of innovative therapies for those experiencing a high burden of disease associated with this form of hemophilia,” he said.The approval could fundamentally transform the treatment paradigm for…
Read More
Mindfulness as Effective as a Commonly Prescribed Antidepressant in Reducing Anxiety

Mindfulness as Effective as a Commonly Prescribed Antidepressant in Reducing Anxiety

Main
A guided mindfulness-based stress reduction program was as effective as use of the gold-standard drug — the antidepressant escitalopram (sold under the brand names Lexipro and Cipralex, among others) — for people with anxiety disorders, according to the findings of a first-of-its-kind, randomized clinical trial published on November 9 in JAMA Psychiatry.“Our study provides evidence for clinicians, insurers, and healthcare systems to recommend, include, and provide reimbursement for mindfulness-based stress reduction as an effective treatment for anxiety disorders because mindfulness meditation currently is reimbursed by very few providers,” said first author Elizabeth Hoge, MD, director of the anxiety disorders research program and associate professor of psychiatry at Georgetown University School of Medicine in Washington, DC, in a press release.These are exciting findings, says Neda Gould, PhD, associate professor of psychiatry…
Read More
Benign Breast Lumps Are Tied to Increased Cancer Risk Years Later

Benign Breast Lumps Are Tied to Increased Cancer Risk Years Later

Main
Even though many women with abnormal screening mammogram results don’t go on to get breast cancer, a new study suggests their risk is elevated when these tests turn up noncancerous lumps.For the study, researchers examined data on more than 778,000 women ages 50 to 69 who had at least one mammogram at a breast cancer screening center in Spain between 1996 and 2015. During a median follow-up period of 7.6 years, mammograms found noncancerous tissue growth, or benign breast disease, in 2.3 percent of the participants and breast cancer in 1.5 percent.Overall, about 25 out of every 1,000 women with benign breast disease went on to develop breast cancer, compared with 15 out of every 1,000 women without these noncancerous tissue growths, researchers reported February 24, 2022, in the International…
Read More
New COVID Subvariants Take Over the U.S.

New COVID Subvariants Take Over the U.S.

Main
The coronavirus continues to mutate rapidly. In the latter half of August, the BA.5 subvariant made up more than 85 percent of COVID-19 infections in the U.S. Now, just three months later, BA.5 accounts for just under one-quarter of cases while BQ.1 and BQ.1.1 are responsible for nearly half of infections in the country, according to latest data from the Centers for Disease Control and Prevention (CDC).Because the BQ variants are new, more research is needed to determine exactly how harmful they may be. Evidence so far suggests they spread easily but cause milder illness that the original and delta strains of the virus.As the BQ variants have grown, so have the latest COVID-19 numbers. Analysis from The New York Times shows that the daily average of cases has increased by…
Read More
FDA Approves New Treatment for Ovarian Cancer

FDA Approves New Treatment for Ovarian Cancer

Main
The U.S. Food and Drug Administration (FDA) has approved a new drug to treat certain types of ovarian cancer in patients who don’t get optimal outcomes from other medicines.The new drug, mirvetuximab soravtansine-gynx (Elahere), is cleared for some patients who have what’s known as epithelial ovarian cancer (the most common form of these malignancies according to MedlinePlus), as well as cancers in the fallopian tubes and peritoneum, a delicate membrane that covers the abdominal walls, uterus, bladder, and rectum.Elahere is approved only for patients with a specific type of cancer known as folate receptor alpha-positive platinum-resistant disease who have previously received so-called systemic treatments like chemotherapy, immunotherapy, or hormone therapy, the FDA said in a statement. Separately, the FDA approved a diagnostic test that can identify patients with tumors that…
Read More
‘Good’ Cholesterol May Not Be as Good as We Thought

‘Good’ Cholesterol May Not Be as Good as We Thought

Main
For decades now, high levels of HDL (high-density lipoprotein) cholesterol — also called “good” cholesterol — have been said to lower the likelihood for heart disease and stroke, per the Centers for Disease Control and Prevention (CDC). New research, however, challenges HDL’s role in predicting cardiovascular risk.Published this month in the Journal of the American College of Cardiology, the study — which was supported by the National Institutes of Health — confirmed that low levels of HDL cholesterol indicated a greater risk of heart attacks or related deaths among white adults — although that did not prove to be the case for Black adults.In addition, the investigation noted that higher HDL cholesterol levels did not appear to be associated with any cardiovascular benefit in either white or Black participants.“The goal was…
Read More
Experimental Alzheimer’s Drug Slows Cognitive Decline

Experimental Alzheimer’s Drug Slows Cognitive Decline

Main
The experimental Alzheimer’s disease drug lecanemab slowed cognitive decline in some people with early Alzheimer’s disease but also caused serious side effects in some patients, according to new results from a late-stage clinical trial.Lecanemab is in a family of medicines designed to clear the brain of plaques formed by the buildup of a protein known as beta-amyloid, which is thought to play a role in the development of Alzheimer’s disease.The new results, published November 29 in the New England Journal of Medicine (NEJM), offer a more detailed look at the effectiveness and safety of the drug two months after its developers, the drugmakers Biogen and Eisai, released preliminary findings from this 18-month clinical trial highlighting that lecanemab slowed cognitive decline by 27 percent.“In persons with early Alzheimer’s disease, lecanemab reduced…
Read More
More Evidence Lung Cancer Screening Boosts Survival Odds

More Evidence Lung Cancer Screening Boosts Survival Odds

Main
Patients diagnosed with lung cancer may have better long-term survival rates when it’s caught early by low-dose computerized tomography (CT) scans, a new study suggests.The U.S. Preventive Services Task Force recommends annual lung cancer screening with low-dose CT in adults ages 50 to 80 years who have a 20 pack-year smoking history, which equals at least a pack a day for 20 years, and who currently smoke or have quit within the past 15 years. But less than 6 percent of people eligible for lung cancer screening get it, according to the American Lung Association.For the new study, researchers examined data on 20-year survival rates for 1,285 patients diagnosed with early-stage lung cancer after undergoing screening with low-dose CT scans.Overall, the 20-year survival rate was 80 percent, according to preliminary…
Read More
Monkeypox Is Renamed ‘Mpox’ to Reduce Stigma

Monkeypox Is Renamed ‘Mpox’ to Reduce Stigma

Main
Monkeypox will now be officially referred to as “mpox,” according to an announcement by the World Health Organization (WHO) on Monday. Both names will be used simultaneously for one year while “monkeypox” is phased out.The Centers for Disease Control and Prevention (CDC) has followed suit and is also updating its website with the term “mpox.”The WHO made the change in an effort to fight racism, discrimination, and stigma that has been associated with the disease, which primarily affects men who have sex with men.“In several meetings, public and private, a number of individuals and countries raised concerns and asked WHO to propose a way forward to change the name,” wrote the organization.The push to rename the disease began in June 2022, when a group of international scientists declared in a statement the urgent need to use…
Read More